|
|||||
|
|
Safety profiles of biologic agents for inflammatory bowel diseases: a prospective pharmacovigilance study in Southern Italy |
|
| Authors: | Roberta Roberti Luigi Francesco Iannone Caterina Palleria Caterina De Sarro Rocco Spagnuolo Maria Antonietta Barbieri |
| Affiliation: | 1. Science of Health Department, School of Medicine, University of Catanzaro, Catanzaro, Italy;2. Department of Clinical and Experimental Medicine, University of Catanzaro, Catanzaro, Italy !["ORCID]({"type":"image","src":"/templates/jsp/images/orcid.png"} "\"ORCID") https://orcid.org/0000-0002-0871-4644;3. Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy |
| Abstract: | Abstract IntroductionInflammatory bowel diseases (IBDs) are a public health issue with over 3.5 million patients in Europe, but the advent of several biologic agents has completely changed their management. Pharmacovigilance is needed to early detect expected/unexpected adverse events (AEs) to assess the safety of drugs in a real-world setting. Aim of this prospective pharmacovigilance study was to evaluate the occurrence of AEs in patients treated with biologic drugs in gastroenterology units in Southern Italy. |
| Keywords: | Adverse events biologics inflammatory bowel diseases pharmacovigilance |